Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP Study: DX-2930 for Long-Term Prophylaxis in Hereditary Angioedema
DRKS00010438Phase 3Active, not recruiting
- Sponsor
- Dyax Corp.
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of lanadelumab in hereditary angioedema (HAE) (4 arms), sponsored by Dyax Corp. Primary endpoint: Efficacy: reduction in acute hereditary angioedema attack rate. Started Apr 2016; status: active, not recruiting.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on DRKS00010438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010438.